Developer docs
API playgroundTry for free, no card

Search company profiles

Abogen Biosciences

Full company profile

uuid0000d26

Namestring
Abogen Biosciences
Legal namestring
Suzhou Abogen Biosciences Co., Ltd.
Websiteurl
abogenbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Abogen Biosciences (Suzhou Abogen Biosciences Co., Ltd., 苏州艾博生物科技有限公司) is a privately held, clinical-stage biotechnology company founded in January 2019 and headquartered in Suzhou Industrial Park, China, with additional offices in Wuxi, Shanghai, and Beijing and approximately 251–500 employees. The company develops nucleic acid-based therapeutics and vaccines built on a proprietary xRNA technology platform that spans three RNA modalities — linear mRNA, circular RNA (via its Cis-System), and self-amplifying RNA (saRNA) — paired with a proprietary Lipid Nanoparticle (LNP) delivery system, a proprietary nucleoside base modification that bypasses m1Ψ patent barriers, and a lyophilized formulation enabling 2–8°C stability for 2–3 years. Core technology infrastructure includes dynamic precision mixing for LNP encapsulation (>90% efficiency), AI-driven ionizable lipid design, miRNA-responsive circRNA expression, and a protein structure design platform for antigen optimization.

The company's pipeline addresses three primary therapeutic verticals: infectious disease (ARCoV/AWcorna COVID-19 vaccine — EUA in Indonesia; ABO1108 lyophilized shingles vaccine in Phase III as the world's first mRNA shingles candidate in Phase III; RSV vaccine with NMPA IND; a nasal-spray TB vaccine co-developed with Malaysia's UKM), oncology/immuno-oncology (ABO2203 mRNA-encoded CD3×CD19 T-cell engager with 100% ORR in high-dose Phase 1 cohort for R/R B-NHL; ABO2102 multi-KRAS mRNA cancer vaccine with dual China/U.S. IND), and autoimmune disease (mRNA-encoded bispecific antibodies for B-cell depletion), with a secondary protein-replacement therapy segment. Platform-level LNP safety has been validated in 30,000+ Phase III participants globally across Indonesia, UAE, and the Philippines.

Abogen's revenue model combines three streams: vaccine product sales (primarily through the Indonesia EUA and government-channel distribution), asset out-licensing of regional or global rights to pipeline programs in infectious disease and oncology, and platform technology licensing for partners developing genetic medicines on the xRNA/LNP stack. Commercial pricing is not publicly disclosed. The company has raised over $1.1 billion across Series A (RMB 150M, Oct 2020), Series B (RMB 600M, Apr 2021), Series C ($700M+, Aug 2021, led by Temasek/Invesco), and Series C+ ($300M, Nov 2021, led by SoftBank Vision Fund). Strategic partnerships include PT Etana Biotechnologies Indonesia (manufacturing technology transfer), PLA Academy of Military Sciences and Walvax Biotechnology (COVID-19 co-development), and Ruijin Hospital (oncology/autoimmune research institute). The company remains pre-revenue commercially and is led by Founder/Chairman/CEO Dr. Bo Ying.

Short descriptiontext

Abogen Biosciences is a clinical-stage Chinese biotech developing mRNA, circRNA, and saRNA therapeutics and vaccines across infectious disease, oncology, and autoimmune indications, using a proprietary LNP delivery platform validated in 30,000+ trial participants, with one COVID-19 vaccine authorized in Indonesia and a shingles vaccine now in Phase III.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA vaccines, nucleic acid therapeutics, lipid nanoparticle delivery, cancer immunotherapy, infectious disease vaccines
Industry5 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
mRNA Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

Revenue from sale of mRNA vaccine products including COVID-19 vaccine (ARCoV/AWcorna) and pipeline vaccines for infectious diseases. Currently commercialized in Indonesia under EUA with manufacturing license obtained November 2021.

abogenbio.com
2Asset Out-licensing
TypeLicensing Royalties
Description

Licensing of global or regional rights of pipeline assets including infectious disease and cancer vaccines as well as protein replacement therapy for autoimmune diseases.

abogenbio.com
3Platform Technology Licensing
TypeLicensing Royalties
Description

Research collaborations with companies utilizing Abogen's end-to-end technology platform to develop genetic medicines.

abogenbio.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AWcorna
Description

Commercial brand name for Abogen's COVID-19 mRNA vaccine ARCoV that received Emergency Use Authorization in Indonesia.

abogenbio.com
Core offering1 text field

Abogen Biosciences is a clinical-stage biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases, oncology, and autoimmune disorders. Its integrated offering covers an end-to-end xRNA platform spanning linear mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA) technologies paired with a proprietary lipid nanoparticle (LNP) delivery system and AI-driven design capabilities. The company's pipeline includes a COVID-19 vaccine authorized in Indonesia, a lyophilized mRNA shingles vaccine in Phase III, a KRAS mRNA cancer vaccine with dual IND approvals, an RSV vaccine, and CD3×CD19 T-cell engager for B-cell non-Hodgkin lymphoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% objective response rate in high-dose cohort of ABO2203 Phase 1 trial for R/R B-NHL
+3 more records
Product overview1 text field

Abogen Biosciences is a clinical-stage biotech company offering an integrated mRNA drug development platform and pipeline of mRNA-based vaccines and therapeutics. The core offering is the xRNA Platform covering mRNA, circRNA, and saRNA technologies, complemented by a proprietary LNP delivery system and AI-driven design capabilities. Key products include: ARCoV/AWcorna COVID-19 vaccine (EUA in Indonesia), ABO2203 CD3×CD19 T-cell engager for NHL, ABO2102 KRAS mRNA cancer vaccine (dual IND approved), ABO1108 shingles vaccine (Phase III), lyophilized RSV vaccine (IND approved), and a nasal spray TB vaccine (National Key R&D Program). The company provides end-to-end capabilities from mRNA design through GMP manufacturing, with formulation options including liquid, lyophilized, and frozen formats.

Product and service5 records
1ARCoV/AWcorna COVID-19 mRNA Vaccine
CategoryInfectious Disease Vaccine
Description

mRNA COVID-19 vaccine co-developed with the PLA Academy of Military Sciences and Walvax Biotechnology; received Emergency Use Authorization in Indonesia in September 2022, becoming China's first internationally approved mRNA vaccine for primary and booster immunization in adults.

2ABO2102 KRAS mRNA Cancer Vaccine
CategoryOncology Therapeutic Vaccine
Description

Therapeutic mRNA cancer vaccine encoding five common KRAS-mutant antigens to activate CD8+ cytotoxic T cells and CD4+ helper T cells against solid tumors; received dual IND approval from China NMPA and U.S. FDA in 2025.

3ABO1108 Lyophilized mRNA Shingles Vaccine
CategoryInfectious Disease Vaccine
Description

Lyophilized mRNA vaccine for herpes zoster (shingles) using a structurally optimized gE protein antigen design with proprietary nucleoside base modification and LNP delivery; world's first mRNA shingles vaccine to enter Phase III clinical development.

4Lyophilized RSV mRNA Vaccine
CategoryInfectious Disease Vaccine
Description

Respiratory syncytial virus mRNA vaccine employing proprietary nucleoside base modification technology and a patented LNP delivery system, with lyophilized formulation maintaining stability for over two years at 2-8°C.

5ABO2203 mRNA-Encoded CD3×CD19 T-cell Engager
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Joint project under China's National Key R&D Programme to develop nasal spray mRNA tuberculosis vaccine using mucosal-anchored adjuvant nanoparticle delivery technology. Combines Abogen's ionizable lipid library validated in 30,000+ participants with UKM's specialized MARE mucosal-anchored adjuvant LNP platform.

2Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Jointly established Ruijin-Abogen Nucleic Acid Drug Research Institute for clinical translation of mRNA drugs in oncology and autoimmune diseases. Multiple projects已进入 investigator-initiated clinical trials (IIT) covering lung cancer, pancreatic cancer, and colorectal cancer.

abogenbio.com
3PT Etana Biotechnologies Indonesia
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Manufacturing partnership to build mRNA vaccine production facility in Indonesia through technology transfer. Factory will be first of its kind in Southeast Asia, equipped with capabilities for pandemic response and access to Abogen's expanding portfolio of mRNA therapeutic products.

abogenbio.com
4People's Liberation Army (PLA) Academy of Military Sciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner for COVID-19 mRNA vaccine development. Military research institution collaborating on vaccine research and development.

abogenbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner for COVID-19 mRNA vaccine ARCoV. Collaborated on vaccine development, clinical trials, and manufacturing.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Participation in WHO and Medicines Patent Pool initiative for global mRNA technology transfer to enhance equitable access to mRNA vaccines worldwide.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global mRNA therapeutics leader (Comirnaty COVID-19 vaccine with Pfizer; oncology pipeline). Directly comparable to Abogen as a pure-play mRNA platform company pursuing infectious disease vaccines and oncology therapeutics, with overlapping modality (mRNA + LNP) and target indications.

TypeDirect peer
Description

Global mRNA therapeutics leader with approved COVID-19, RSV, and flu vaccines plus an oncology and rare disease pipeline. Most directly comparable mRNA peer; Abogen's Chief AI Officer (Dr. McFadyen) is a former Moderna VP who built its computational science function.

3Stemirna Therapeutics
TypeDirect peer
Description

Chinese clinical-stage mRNA biotech developing COVID-19, infectious disease, and oncology vaccines using mRNA and LNP platforms. Closest head-to-head Chinese competitor to Abogen with similar platform technology, target indications, and China-based regulatory pathway.

TypeDirect peer
Description

German mRNA therapeutics company developing prophylactic vaccines, oncology, and protein replacement therapies. Comparable modality (mRNA platform with proprietary delivery) and similar clinical-stage positioning, with overlapping focus on infectious disease and oncology.

TypeDirect peer
Description

US clinical-stage mRNA company with self-amplifying RNA (saRNA) platform and LNP delivery system. Directly comparable to Abogen's xRNA platform (mRNA/circRNA/saRNA) and pursues similar infectious disease and rare disease indications with comparable clinical-stage profile.

TypeDirect peer
Description

Chinese vaccine developer with approved viral-vector COVID-19 vaccine and expanding mRNA pipeline. Comparable as a leading Chinese vaccine innovator pursuing both viral vector and mRNA modalities for infectious disease, with similar target markets and regulatory pathways.

TypeDirect peer
Description

Chinese vaccine manufacturer and Abogen's co-development partner on the ARCoV COVID-19 mRNA vaccine. Comparable as a Chinese mRNA vaccine developer/manufacturer with overlapping pipeline and similar distribution focus on domestic and emerging markets.

8Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines business of Sanofi with established franchises in influenza, pediatric, and travel vaccines; actively expanding into mRNA through Translate Bio acquisition and internal programs. Broad incumbent competitor in infectious disease vaccines that Abogen's mRNA platform aims to disrupt.

TypeBroad incumbent
Description

Major global vaccines business with established shingles (Shingrix), hepatitis, and pediatric vaccine franchises. Directly relevant incumbent for the shingles vaccine market that Abogen's ABO1108 Phase III mRNA candidate targets.

TypeBroad incumbent
Description

Large Chinese pharmaceutical conglomerate with growing mRNA vaccine and biologics pipeline. Comparable as a major Chinese pharma pursuing mRNA and other modalities for infectious disease and oncology, providing context on domestic scale and competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors39 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abogen Biosciences

mRNA Biopharmaceuticalsabogenbio.com

Abogen Biosciences is a clinical-stage Chinese biotech developing mRNA, circRNA, and saRNA therapeutics and vaccines across infectious disease, oncology, and autoimmune indications, using a proprietary LNP delivery platform validated in 30,000+ trial participants, with one COVID-19 vaccine authorized in Indonesia and a shingles vaccine now in Phase III.

What Abogen Biosciences does

Abogen Biosciences (Suzhou Abogen Biosciences Co., Ltd., 苏州艾博生物科技有限公司) is a privately held, clinical-stage biotechnology company founded in January 2019 and headquartered in Suzhou Industrial Park, China, with additional offices in Wuxi, Shanghai, and Beijing and approximately 251–500 employees. The company develops nucleic acid-based therapeutics and vaccines built on a proprietary xRNA technology platform that spans three RNA modalities — linear mRNA, circular RNA (via its Cis-System), and self-amplifying RNA (saRNA) — paired with a proprietary Lipid Nanoparticle (LNP) delivery system, a proprietary nucleoside base modification that bypasses m1Ψ patent barriers, and a lyophilized formulation enabling 2–8°C stability for 2–3 years. Core technology infrastructure includes dynamic precision mixing for LNP encapsulation (>90% efficiency), AI-driven ionizable lipid design, miRNA-responsive circRNA expression, and a protein structure design platform for antigen optimization.

The company's pipeline addresses three primary therapeutic verticals: infectious disease (ARCoV/AWcorna COVID-19 vaccine — EUA in Indonesia; ABO1108 lyophilized shingles vaccine in Phase III as the world's first mRNA shingles candidate in Phase III; RSV vaccine with NMPA IND; a nasal-spray TB vaccine co-developed with Malaysia's UKM), oncology/immuno-oncology (ABO2203 mRNA-encoded CD3×CD19 T-cell engager with 100% ORR in high-dose Phase 1 cohort for R/R B-NHL; ABO2102 multi-KRAS mRNA cancer vaccine with dual China/U.S. IND), and autoimmune disease (mRNA-encoded bispecific antibodies for B-cell depletion), with a secondary protein-replacement therapy segment. Platform-level LNP safety has been validated in 30,000+ Phase III participants globally across Indonesia, UAE, and the Philippines.

Abogen's revenue model combines three streams: vaccine product sales (primarily through the Indonesia EUA and government-channel distribution), asset out-licensing of regional or global rights to pipeline programs in infectious disease and oncology, and platform technology licensing for partners developing genetic medicines on the xRNA/LNP stack. Commercial pricing is not publicly disclosed. The company has raised over $1.1 billion across Series A (RMB 150M, Oct 2020), Series B (RMB 600M, Apr 2021), Series C ($700M+, Aug 2021, led by Temasek/Invesco), and Series C+ ($300M, Nov 2021, led by SoftBank Vision Fund). Strategic partnerships include PT Etana Biotechnologies Indonesia (manufacturing technology transfer), PLA Academy of Military Sciences and Walvax Biotechnology (COVID-19 co-development), and Ruijin Hospital (oncology/autoimmune research institute). The company remains pre-revenue commercially and is led by Founder/Chairman/CEO Dr. Bo Ying.

Abogen Biosciences firmographics

Firmographics
Name
Abogen Biosciences
Legal name
Suzhou Abogen Biosciences Co., Ltd.
Website
https://abogenbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Abogen Biosciences is a clinical-stage Chinese biotech developing mRNA, circRNA, and saRNA therapeutics and vaccines across infectious disease, oncology, and autoimmune indications, using a proprietary LNP delivery platform validated in 30,000+ trial participants, with one COVID-19 vaccine authorized in Indonesia and a shingles vaccine now in Phase III.
Ownership category
akta.pro rank

Abogen Biosciences industry classification

Industry
Product category
mRNA Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • MRNA vaccines
  • Nucleic acid therapeutics
  • Lipid nanoparticle delivery
  • Cancer immunotherapy
  • Infectious disease vaccines

Where Abogen Biosciences is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Abogen Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Vaccine Product Sales: Revenue from sale of mRNA vaccine products including COVID-19 vaccine (ARCoV/AWcorna) and pipeline vaccines for infectious diseases. Currently commercialized in Indonesia under EUA with manufacturing license obtained November 2021.
  2. Asset Out-licensing: Licensing of global or regional rights of pipeline assets including infectious disease and cancer vaccines as well as protein replacement therapy for autoimmune diseases.
  3. Platform Technology Licensing: Research collaborations with companies utilizing Abogen's end-to-end technology platform to develop genetic medicines.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Abogen Biosciences product offering

Product offering

Core offering

Abogen Biosciences is a clinical-stage biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases, oncology, and autoimmune disorders. Its integrated offering covers an end-to-end xRNA platform spanning linear mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA) technologies paired with a proprietary lipid nanoparticle (LNP) delivery system and AI-driven design capabilities. The company's pipeline includes a COVID-19 vaccine authorized in Indonesia, a lyophilized mRNA shingles vaccine in Phase III, a KRAS mRNA cancer vaccine with dual IND approvals, an RSV vaccine, and CD3×CD19 T-cell engager for B-cell non-Hodgkin lymphoma.

Product overview

Abogen Biosciences is a clinical-stage biotech company offering an integrated mRNA drug development platform and pipeline of mRNA-based vaccines and therapeutics. The core offering is the xRNA Platform covering mRNA, circRNA, and saRNA technologies, complemented by a proprietary LNP delivery system and AI-driven design capabilities. Key products include: ARCoV/AWcorna COVID-19 vaccine (EUA in Indonesia), ABO2203 CD3×CD19 T-cell engager for NHL, ABO2102 KRAS mRNA cancer vaccine (dual IND approved), ABO1108 shingles vaccine (Phase III), lyophilized RSV vaccine (IND approved), and a nasal spray TB vaccine (National Key R&D Program). The company provides end-to-end capabilities from mRNA design through GMP manufacturing, with formulation options including liquid, lyophilized, and frozen formats.

Differentiator

Problem solved

Functional benefit

Brands

  • AWcorna: Commercial brand name for Abogen's COVID-19 mRNA vaccine ARCoV that received Emergency Use Authorization in Indonesia.

Products and services

  • ARCoV/AWcorna COVID-19 mRNA Vaccine mRNA COVID-19 vaccine co-developed with the PLA Academy of Military Sciences and Walvax Biotechnology; received Emergency Use Authorization in Indonesia in September 2022, becoming China's first internationally approved mRNA vaccine for primary and booster immunization in adults.
  • ABO2102 KRAS mRNA Cancer Vaccine Therapeutic mRNA cancer vaccine encoding five common KRAS-mutant antigens to activate CD8+ cytotoxic T cells and CD4+ helper T cells against solid tumors; received dual IND approval from China NMPA and U.S. FDA in 2025.
  • ABO1108 Lyophilized mRNA Shingles Vaccine Lyophilized mRNA vaccine for herpes zoster (shingles) using a structurally optimized gE protein antigen design with proprietary nucleoside base modification and LNP delivery; world's first mRNA shingles vaccine to enter Phase III clinical development.
  • Lyophilized RSV mRNA Vaccine Respiratory syncytial virus mRNA vaccine employing proprietary nucleoside base modification technology and a patented LNP delivery system, with lyophilized formulation maintaining stability for over two years at 2-8°C.
  • ABO2203 mRNA-Encoded CD3×CD19 T-cell Engager

Quantifiable outcome

  • 100% objective response rate in high-dose cohort of ABO2203 Phase 1 trial for R/R B-NHL
  • +3 more outcomes

Companies that use Abogen Biosciences

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Abogen Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Abogen Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • National University of Malaysia (UKM)flagshipStrategic or Co-development Partner · 1 January 2025Joint project under China's National Key R&D Programme to develop nasal spray mRNA tuberculosis vaccine using mucosal-anchored adjuvant nanoparticle delivery technology. Combines Abogen's ionizable lipid library validated in 30,000+ participants with UKM's specialized MARE mucosal-anchored adjuvant LNP platform.
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineflagshipStrategic or Co-development Partner · 1 June 2024Jointly established Ruijin-Abogen Nucleic Acid Drug Research Institute for clinical translation of mRNA drugs in oncology and autoimmune diseases. Multiple projects已进入 investigator-initiated clinical trials (IIT) covering lung cancer, pancreatic cancer, and colorectal cancer.
  • PT Etana Biotechnologies IndonesiaflagshipStrategic or Co-development Partner · 1 July 2022Manufacturing partnership to build mRNA vaccine production facility in Indonesia through technology transfer. Factory will be first of its kind in Southeast Asia, equipped with capabilities for pandemic response and access to Abogen's expanding portfolio of mRNA therapeutic products.
  • People's Liberation Army (PLA) Academy of Military SciencescoreStrategic or Co-development PartnerCo-development partner for COVID-19 mRNA vaccine development. Military research institution collaborating on vaccine research and development.
  • Walvax Biotechnology Co., Ltd.coreStrategic or Co-development PartnerCo-development partner for COVID-19 mRNA vaccine ARCoV. Collaborated on vaccine development, clinical trials, and manufacturing.
  • WHO/MPP mRNA Technology Transfer ProgrammeflagshipStrategic or Co-development PartnerParticipation in WHO and Medicines Patent Pool initiative for global mRNA technology transfer to enhance equitable access to mRNA vaccines worldwide.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Abogen Biosciences competitors and assessment

Company assessment

Direct peers

  • BioNTech: Global mRNA therapeutics leader (Comirnaty COVID-19 vaccine with Pfizer; oncology pipeline). Directly comparable to Abogen as a pure-play mRNA platform company pursuing infectious disease vaccines and oncology therapeutics, with overlapping modality (mRNA + LNP) and target indications.
  • Moderna: Global mRNA therapeutics leader with approved COVID-19, RSV, and flu vaccines plus an oncology and rare disease pipeline. Most directly comparable mRNA peer; Abogen's Chief AI Officer (Dr. McFadyen) is a former Moderna VP who built its computational science function.
  • Stemirna Therapeutics: Chinese clinical-stage mRNA biotech developing COVID-19, infectious disease, and oncology vaccines using mRNA and LNP platforms. Closest head-to-head Chinese competitor to Abogen with similar platform technology, target indications, and China-based regulatory pathway.
  • CureVac: German mRNA therapeutics company developing prophylactic vaccines, oncology, and protein replacement therapies. Comparable modality (mRNA platform with proprietary delivery) and similar clinical-stage positioning, with overlapping focus on infectious disease and oncology.
  • Arcturus Therapeutics: US clinical-stage mRNA company with self-amplifying RNA (saRNA) platform and LNP delivery system. Directly comparable to Abogen's xRNA platform (mRNA/circRNA/saRNA) and pursues similar infectious disease and rare disease indications with comparable clinical-stage profile.
  • CanSino Biologics: Chinese vaccine developer with approved viral-vector COVID-19 vaccine and expanding mRNA pipeline. Comparable as a leading Chinese vaccine innovator pursuing both viral vector and mRNA modalities for infectious disease, with similar target markets and regulatory pathways.
  • Walvax Biotechnology: Chinese vaccine manufacturer and Abogen's co-development partner on the ARCoV COVID-19 mRNA vaccine. Comparable as a Chinese mRNA vaccine developer/manufacturer with overlapping pipeline and similar distribution focus on domestic and emerging markets.

Broad incumbents

  • Sanofi Pasteur: Global vaccines business of Sanofi with established franchises in influenza, pediatric, and travel vaccines; actively expanding into mRNA through Translate Bio acquisition and internal programs. Broad incumbent competitor in infectious disease vaccines that Abogen's mRNA platform aims to disrupt.
  • GSK Vaccines: Major global vaccines business with established shingles (Shingrix), hepatitis, and pediatric vaccine franchises. Directly relevant incumbent for the shingles vaccine market that Abogen's ABO1108 Phase III mRNA candidate targets.
  • CSPC Pharmaceutical Group: Large Chinese pharmaceutical conglomerate with growing mRNA vaccine and biologics pipeline. Comparable as a major Chinese pharma pursuing mRNA and other modalities for infectious disease and oncology, providing context on domestic scale and competition.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Abogen Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abogen Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Abogen Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Abogen Biosciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors39 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abogen Biosciences M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abogen Biosciences

What does Abogen Biosciences do?

Abogen Biosciences is a clinical-stage biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases, oncology, and autoimmune disorders. Its integrated offering covers an end-to-end xRNA platform spanning linear mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA) technologies paired with a proprietary lipid nanoparticle (LNP) delivery system and AI-driven design capabilities. The company's pipeline includes a COVID-19 vaccine authorized in Indonesia, a lyophilized mRNA shingles vaccine in Phase III, a KRAS mRNA cancer vaccine with dual IND approvals, an RSV vaccine, and CD3×CD19 T-cell engager for B-cell non-Hodgkin lymphoma.

Is Abogen Biosciences a public or private company?

Abogen Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abogen Biosciences founded?

Abogen Biosciences was founded in 2019. It employs 101 to 250 people.

Where is Abogen Biosciences based?

Abogen Biosciences is headquartered in Suzhou, China, in the Asia region.

How does Abogen Biosciences make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are asset Out-licensing and platform Technology Licensing.

Who are Abogen Biosciences's main competitors?

Direct peers on record are BioNTech, Moderna, Stemirna Therapeutics, CureVac, Arcturus Therapeutics, CanSino Biologics and Walvax Biotechnology. Broad incumbents are Sanofi Pasteur, GSK Vaccines and CSPC Pharmaceutical Group.

Does Abogen Biosciences have an API?

No public API is recorded for Abogen Biosciences.

What industry is Abogen Biosciences in?

Abogen Biosciences's product category is mRNA Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerHealthcare Stocks Fall Slightly -- Healthcare RoundupHealthcare stocks edged lower as a risk-on mood weighed on the defensive sector. Novartis agreed to license an mRNA drug candidate from Abogen Biosciences for up to $7.8 billion, gaining options on future therapies. The deal reflects drugmakers' focus on China to bolster pipelines as older medicines face patent expiration.MorningstarHealthcare Stocks Fall Slightly — Healthcare RoundupHealthcare stocks edged lower as a risk-on mood weighed on the defensive sector. Novartis agreed to license an mRNA drug candidate from Abogen Biosciences for up to $7.8 billion, seeking China to fill its pipeline. Many drugmakers are targeting China for new drug ideas as older medicines face patent expiration.MarketScreenerNovartis signs mRNA deal for about $7.8 billion with China's AbogenNovartis signed a licensing deal with Abogen worth about $7.8 billion to advance RNA-based therapy. Abogen receives $575 million upfront, with potential additional $7.2 billion if the drug advances and wins approval. The deal covers ABO2203, targeting autoimmune diseases like lupus and rheumatoid arthritis.The Edge MalaysiaNovartis inks Chinese mRNA-therapy deal for up to US$7.8 bilNovartis licensed Abogen Biosciences' mRNA-based autoimmune therapy ABO2203 for up to $7.8 billion, paying $575 million upfront. The deal covers options for other RNA platform programs, with potential additional payments and royalties. Novartis has paused clinical trials after three patient deaths.ReutersNovartis signs mRNA deal for about $7.8 billion with China's AbogenNovartis signed a licensing deal worth about $7.8 billion with Chinese biotech Abogen to advance RNA-based therapy. Novartis gets exclusive rights to Abogen's drug ABO2203, with $575 million upfront and potential additional $7.2 billion. The drug targets B cells for autoimmune diseases like lupus and rheumatoid arthritis.The future of tradingNovartis strikes about $7.8 billion mRNA deal with China's AbogenAbogen signed a licensing and option agreement worth about $7.8 billion with Novartis to advance RNA-based therapy. The deal was announced on Friday.The future of tradingAbogen Biosciences signs licensing, option deal with Novartis for ABO2203 mRNA T-cell engagerAbogen Biosciences signed a licensing and option deal with Novartis for ABO2203, an mRNA-encoded CD19xCD3 T-cell engager. Novartis receives an exclusive worldwide license, and Abogen will get $575 million upfront, with potential milestones up to about $7.2 billion.TradingViewNovartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — UpdateNovartis agreed to license Abogen's mRNA drug candidate ABO2203 for up to $7.8 billion, paying $575 million upfront. The deal gives Novartis worldwide rights and options on future RNA platform assets, following similar China partnerships.European BiotechnologyNovartis bets up to $7.8B on Abogen’s mRNA autoimmune therapyNovartis paid Abogen Biosciences $575 million upfront for global rights to ABO2203, an mRNA-based B-cell depleting therapy. The deal includes up to $7.2 billion in milestones and royalties, following Novartis's pause on its CAR-T autoimmune trials. ABO2203 is in Phase 1 trials for autoimmune diseases and lymphoma.BloombergNovartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 BillionNovartis will license an mRNA-based autoimmune therapy from China's Abogen Biosciences in a deal worth up to $7.8 billion. The Swiss drugmaker will pay $575 million upfront for rights to an mRNA-encoded T-cell engager that makes the patient's body produce the therapeutic molecule.